This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Learn about ATTR-CM and uncover the differences between hereditary and wild-type ATTR-CM
Menu
Close
Click here for Vyndaqel®▼ (tafamidis) Prescribing Information.
Current standard of care treatment options available for ATTR-CM are aimed at symptom management, supportive care including pain management, nutritional and mobility support and mitigation of the effects of the disease on other organs.1
In February 2020, marketing authorisation in the United Kingdom was granted for Vyndaqel▼ (tafamidis), a transthyretin stabiliser, available as a once-daily 61 mg oral capsule, for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).2,3
As of 19th June 2024, Vyndaqel (tafamidis) is recommended by NICE as an option for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in adults.4
Tafamidis is only recommended if the company provides it according to the commercial arrangement.
To learn about what this means for your eligible patients, follow the link below.
Please note that this links to a Pfizer promotional website intended for UK healthcare professionals only.
ATTR-CM=transthyretin amyloid cardiomyopathy,NICE= National Institute for Health and Care Excellence
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024